Clinical Trial Update: Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating sublingual 5-MeO-DMT for reducing anxiety and depressive symptoms in individuals with mild cognitive impairment reports efficacy si…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Cognitive Impairment
• Depressive Disorders

Drugs mentioned

• Sublingual 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT))

Snippet

Sponsor: Biomind Labs Inc. | Conditions: Mild Cognitive Impairment, Anxiety State | Phase 1, Phase 2 | Status: COMPLETED